title: Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections.
abstract: Resistance among Gram-positive organisms has been steadily increasing over the last several years; however, the development of new antibiotics to treat infections caused from these organisms has fallen short of the emergent need. Specifically, resistance among Staphylococcus aureus and Enterococcus spp. to essential antibiotics is considered a major problem. Oritavancin is a semisynthetic lipoglycopeptide antibiotic that was recently approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). While structurally related to vancomycin, oritavancin also possesses unique mechanisms of action that greatly enhance its antimicrobial potency against multi-drug resistant pathogens including both VanA- and VanB-mediated vancomycin-resistant enterococci. Owing to the addition of the highly hydrophobic tail group, oritavancin possesses a prolonged half-life ranging from 200-300 h. Although oritavancin is only currently Food and Drug Administration approved for ABSSSI, this agent may eventually play a role in additional indications where new innovative therapy is needed including bacteremia and deep-seeded, Gram-positive infections such as infective endocarditis or osteomyelitis. This review will focus on oritavancin's spectrum of activity, mechanisms of action and resistance, pharmacokinetic and pharmacodynamic properties, and the completed and ongoing clinical studies evaluating its use.
authors.affiliation: Saint Vincent Hospital Indianapolis, Indianapolis, IN, USA.
authors.forename: Karrine D
authors.initials: KD
authors.lastname: Brade
authors.affiliation: Department of Clinical Pharmacy, University of Tennessee Health Science Center, Memphis, TN, USA.
authors.forename: Jeffrey M
authors.initials: JM
authors.lastname: Rybak
authors.affiliation: Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA. m.rybak@wayne.edu.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Rybak
keywords: Acute bacterial skin and skin structure infection; Lipoglycopeptide; Oritavancin
references.citation: Antimicrob Agents Chemother. 2009 Mar;53(3):918-25
references.pmid: 19104027
references.citation: J Antimicrob Chemother. 2013 Jan;68(1):164-7
references.pmid: 22941898
references.citation: Antimicrob Agents Chemother. 1997 Oct;41(10):2165-72
references.pmid: 9333042
references.citation: Antimicrob Agents Chemother. 2005 Jan;49(1):148-52
references.pmid: 15616289
references.citation: N Engl J Med. 2014 Jun 5;370(23):2180-90
references.pmid: 24897083
references.citation: Diagn Microbiol Infect Dis. 2014 Mar;78(3):255-62
references.pmid: 24360267
references.citation: Antimicrob Agents Chemother. 1996 Oct;40(10):2291-5
references.pmid: 8891132
references.citation: Antimicrob Agents Chemother. 2003 Feb;47(2):568-76
references.pmid: 12543661
references.citation: Antimicrob Agents Chemother. 2015 Oct;59(10):6501-5
references.pmid: 26239977
references.citation: J Mol Biol. 2009 Oct 9;392(5):1178-91
references.pmid: 19576226
references.citation: Antimicrob Agents Chemother. 2013 Jan;57(1):205-11
references.pmid: 23089749
references.citation: Clin Infect Dis. 2015 Jan 15;60(2):254-62
references.pmid: 25294250
references.citation: Antimicrob Agents Chemother. 2011 Jul;55(7):3476-84
references.pmid: 21537018
references.citation: Biochemistry. 2008 Mar 25;47(12):3822-31
references.pmid: 18302341
references.citation: Antimicrob Agents Chemother. 1998 Apr;42(4):981-3
references.pmid: 9559828
references.citation: Antimicrob Agents Chemother. 2010 Dec;54(12):5369-71
references.pmid: 20876372
references.citation: Antimicrob Agents Chemother. 2015 Feb;59(2):772-81
references.pmid: 25403671
references.citation: J Antimicrob Chemother. 2015 Feb;70(2):498-504
references.pmid: 25362568
references.citation: Antimicrob Agents Chemother. 2014 May;58(5):2921-4
references.pmid: 24550323
references.citation: Antimicrob Agents Chemother. 1999 Jan;43(1):115-20
references.pmid: 9869575
references.citation: Antimicrob Agents Chemother. 2003 May;47(5):1700-6
references.pmid: 12709343
references.citation: Diagn Microbiol Infect Dis. 2004 Oct;50(2):95-102
references.pmid: 15474317
references.citation: J Antibiot (Tokyo). 1996 Jun;49(6):575-81
references.pmid: 8698642
references.citation: J Antimicrob Chemother. 2013 Sep;68(9):2078-82
references.pmid: 23759507
references.citation: Antimicrob Agents Chemother. 2015;59(6):3365-72
references.pmid: 25824211
references.citation: J Antimicrob Chemother. 2009 Oct;64(4):868-70
references.pmid: 19656783
references.citation: Antimicrob Agents Chemother. 2012 Mar;56(3):1639-42
references.pmid: 22183169
references.citation: J Antimicrob Chemother. 2012 Dec;67(12):2919-26
references.pmid: 22899803
references.citation: Diagn Microbiol Infect Dis. 2011 Dec;71(4):470-3
references.pmid: 22018937
references.citation: J Mol Biol. 2009 Aug 14;391(2):414-25
references.pmid: 19538971
references.citation: Antimicrob Agents Chemother. 2001 Jul;45(7):2169-72
references.pmid: 11408247
references.citation: Infect Control Hosp Epidemiol. 2013 Jan;34(1):1-14
references.pmid: 23221186
references.citation: Antimicrob Agents Chemother. 2009 Oct;53(10):4422-8
references.pmid: 19635952
references.citation: J Antimicrob Chemother. 2009 Jun;63(6):1191-9
references.pmid: 19369269
references.citation: J Antimicrob Chemother. 2001 May;47(5):705-7
references.pmid: 11328790
references.citation: J Antimicrob Chemother. 2008 Oct;62(4):762-5
references.pmid: 18606787
references.citation: J Mol Biol. 2008 Mar 14;377(1):281-93
references.pmid: 18258256